Fundraising FoxRepligen
NASDAQ: RGENWaltham, US · Delaware corporation
Find your way into Repligen
Sign up to see every warm intro you have to Repligen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Repligen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Repligen develops bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows. Its solutions serve biopharma and CDMO teams developing modalities such as mAbs, ADCs, mRNA, and cell and gene therapies, from process development through GMP manufacturing.
Founders & leadership
JK
Jon K. SnodgresExecutive
WC
WALTER C. HERLIHYExecutive
JR
JAMES R. RUSCHEExecutive
DP
DANIEL P. WITTExecutive
OL
Olivier LoeillotPresident and Chief Executive Officer, Director
BD
Brian DouglassSenior Vice President, Chief Product Officer
HB
Howard BenjaminNamed on SEC filing
Board
GL
Glenn L. CooperBoard director
TF
Thomas F. Ryan, Jr.Board director
Reported raises · per SEC filings
Form D private placements$290.6M disclosed across 3 rounds · 2014–2019
▶$48MraisedJun 2019 · 1 investors · Other Health CareRule 506(b)
▶$48MraisedJun 2019 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John G. CoxDirector
- Glenn P. MuirDirector
- Tony J. HuntExecutive Officer, Director
- Jon K. SnodgresExecutive Officer
- Ralf J. KuriyelExecutive Officer
- Thomas F. Ryan, Jr.Director
- Karen A. DawesDirector
- Nicolas M. BarthelemyDirector
- Glenn L. CooperDirector
- Offering amount
- $48M
- Amount sold
- $48M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$238.6MraisedAug 2017 · 8 investors · Other Health CareRule 506(b)
▶$238.6MraisedAug 2017 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Howard BenjaminExecutive Officer
- Glenn L. CooperDirector
- Thomas F. Ryan, Jr.Director
- Tony J. HuntExecutive Officer, Director
- Karen A. DawesDirector
- John G. CoxDirector
- Nicolas M. BarthelemyDirector
- Jon K. SnodgresExecutive Officer
- Glenn P. MuirDirector
- Offering amount
- $238.6M
- Amount sold
- $238.6M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJun 2014 · 1 investors · Other TechnologyRule 506(b)
▶$4MraisedJun 2014 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- ANTHONY HUNTExecutive Officer
- WALTER C. HERLIHYExecutive Officer, Director
- ALFRED L. GOLDBERGDirector
- JOHN G. COXDirector
- JAMES R. RUSCHEExecutive Officer
- THOMAS F. RYAN , JR.Director
- GLENN L. COOPERDirector
- MICHAEL A. GRIFFITHDirector
- DANIEL P. WITTExecutive Officer
- HOWARD BENJAMINExecutive Officer
- NICOLAS BARTHELEMYDirector
- KAREN A. DAWESDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 1
Early investors' stakes continue via these dealsTantti
Chromatography innovator acquired by Repligen.
In the news
Frequently asked questions
- What does Repligen do?
- Repligen develops bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows. Its solutions serve biopharma and CDMO teams developing modalities such as mAbs, ADCs, mRNA, and cell and gene therapies, from process development through GMP manufacturing.
- How much funding has Repligen raised?
- Repligen has disclosed $290.6M raised across 3 rounds.
- Where is Repligen headquartered?
- Repligen is headquartered in Waltham, US.